[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"moderate-depression\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:moderate-depression":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,60,105],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":36,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":59},"100606821","creating-health-course-study-for-people-with-rheumatological-conditions-and-mood-disorders-100606821",false,"NCT07180537","Creating Health Course Study for People With Rheumatological Conditions and Mood Disorders","Transforming Health Habits: Evaluating an Online Wellness Program for Individuals With Rheumatological Conditions and Mood Disorders","Inclusion criteria:\n\n1. A diagnosis of one of the following: Rheumatoid Arthritis (RA), Sjogren's Syndrome, Systemic lupus erythematosus (SLE), Mixed connective tissue disease (MCTD), or Psoriatic Arthritis (PsA), as documented by their treating specialist or primary care provider, as reported by the participant.\n2. Must be age 18 and older, at time of consent.\n3. Must be fluent in both speaking and reading English.\n\n   \\*Study participant must be able to read and comprehend informed consent document and speak with study staff about study document content. Study staff will use discretion in determining whether the study participant can clearly communicate with staff and comprehend the study material during the consent call or prior to the call.\n4. Must have access to high-speed internet with devices capable of audio\u002Fvideo streaming.\n5. Must be willing to participate in an online health course designed to improve dietary intake and self-care routines to help improve cellular function and health, and complete online surveys over the course of a 6-month period.\n6. Individuals must pass the Short Portable Mental Status Questionnaire with scores for normal mental functioning (up to 2 errors). Cognitive impairment as measured by the SPMS Questionnaire could interfere with the completion of the online course.\n\nSCORING\\* 0-2 errors: normal mental functioning 3-4 errors: mild cognitive impairment 5-7 errors: moderate cognitive impairment 8-10 errors: severe cognitive impairment\n\n\\*Allow one more error for a subject with only a grade school education. Allow one less error for a subject with education beyond high school.\n\nSource: Pfeiffer, E. (1975). A short portable mental status questionnaire for the assessment of organic brain deficit in elderly patients. Journal of American Geriatrics Society. 23, 433-41.\n\nExclusion criteria:\n\n1. Inability to provide informed consent, including participation in a consent call conducted via Zoom with the study team during business hours (8:00 a.m. to 5:00 p.m. Central Time (Chicago)).\n2. Participation in another research study investigating an intervention (treatments, medications, diet, or exercise). Participation in observation-only studies are not excluded.\n3. Currently following a modified Paleolithic, low-fat nutrient-dense vegetarian, or Mediterranean diet with 75% OR greater reported compliance.\n4. Any diagnosis or condition that is contraindicated from starting a gentle exercise program (ex. poorly controlled diseases of the heart, kidney, or liver in the prior 12 months, or severe psychiatric disease, e.g., schizophrenia, making adherence to study procedures difficult.","ALL","18 Years","100 Years",{"count":20,"type":21},400,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this project is to critically evaluate the effectiveness of an online health program designed to improve diet and self-care in patients with rheumatological conditions, including rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), mixed connective tissue disease (MCTD), psoriatic arthritis (PsA), anxiety disorders, depressive disorders and moderate depression.\n\nAdditionally, investigators will assess the program's effectiveness, as well as the challenges and facilitators involved in using an online wellness program to reduce fatigue and enhance the quality of life in patients suffering from these conditions.",[27,28,29,30,31,32,33,34,35],"Rheumatoid Arthritis","Sjogren's Syndrome","Systemic Lupus Erythematosus","Mixed Connective Tissue Disease","Psoriatic Arthritis","Anxiety Disorders","Depressive Disorders","Moderate Depression","Moderate Anxiety",[37,38,39,40,41,42,43,44,45,46],"diet","self-care","internet course","anxiety","depression","Sjogren's","rheumatoid arthritis","lupus","fatigue","arthritis","RECRUITING","2026-08-06",{"date":50,"type":51},"2026-08-10","ACTUAL",{"date":53,"type":51},"2025-12-01",{"date":55,"type":21},"2027-12-31",{"name":57,"class":58},"Terry L. Wahls","OTHER",1,{"id":61,"slug":62,"hasResults":11,"nctId":63,"briefTitle":64,"officialTitle":65,"acronym":4,"eligibilityCriteria":66,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":22,"phases":70,"briefSummary":72,"conditions":73,"keywords":90,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":59},"100573936","phase-3-nebulized-ketamine-for-the-treatment-of-major-depressive-disorder-100573936","NCT06752759","Nebulized Ketamine for the Treatment of Major Depressive Disorder","Nebulized Ketamine for the Treatment of Major Depressive Disorder in an Inpatient Setting: A Midazolam-controlled Randomized Controlled Trial","Inclusion Criteria:\n\n* All individuals 18 years and older with a Montgomery-Asberg Depression Rating Scale score (MADRS) ≥ 20\n* Must have a diagnosis of moderate to severe Major Depressive Disorder (MDD)\n* Structured Clinical Interview for DSM-5 (SCID-5) will be performed to confirm MDD diagnosis\n\nExclusion Criteria:\n\n* Adult patients with an allergy to Ketamine\n* Adult patients with an allergy to Midazolam\n* Individuals with a history of mania\u002Fhypomania or diagnosis of bipolar disorder\n* Patients on lithium and\u002For lamotrigine therapy\n* Recent or current homicidal ideation with an intent to act\n* MDD with psychotic features or current or past diagnosis of a psychotic disorder\n* No substance use disorder in the preceding 3 months except nicotine or caffeine or a positive urine screen for substances (except cannabis)\n* Diagnosis of obsessive-compulsive disorder, antisocial personality disorder, borderline personality disorder, posttraumatic stress disorder, intellectual disability, altered mental status, pregnant or breastfeeding patients,\n* Patients on \\> 2 medications for hypertension\n* Patients with uncontrolled hypertension (BP \\>140 mm Hg systolic and\u002For \\>90 mm Hg diastolic on two separate readings at the time of screening)\n* Body weight of \\> 150kg\n* Patients with history of congestive cardiac failure\n* Day of presentation, patients with unstable vital signs (systolic blood pressure \\\u003C90 or\\>160 mm Hg, pulse rate \\\u003C50 or \\>150 beats\u002Fmin, and respiration rate \\\u003C10 or \\>30 breaths\u002Fmin)\n* Consumption of opioids within 24 hours of drug administration\n* Acutely intoxicated patients will also be excluded","88 Years",{"count":69,"type":21},40,[71],"PHASE3","This is a double-blind active placebo controlled clinical trial for individuals with moderate to severe depression. The purpose of this study is to assess if nebulized ketamine can reduce depressive symptoms.",[74,34,75,76,77,78,79,80,81,82,83,84,85,86,87,88,89],"Severe Depression","Ketamine","Midazolam","Peripheral Nervous System Agents","Central Nervous System Agents","Neurotransmitter Agents","Physiologic Effects of Drugs","Sensory System Agents","Analgesics, Non-Narcotic","Anti-Inflammatory Agents, Non-Steroidal","Depressive Symptom","Hypnotics and Sedatives","Anti-anxiety Agents","Tranquilizing Agents","Psychotropic Drugs","Anesthetics Agent",[91,92,75,76,77,81,93,94,95],"Maimonides Medical Center","Psychiatry","Anesthetics, Dissociative","Nebulized Medications for depression","GABA Agents","2026-04-21",{"date":98,"type":51},"2026-04-24",{"date":100,"type":51},"2024-10-16",{"date":102,"type":21},"2027-09-30",{"name":104,"class":58},"Theresa Jacob, PhD, MPH",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":110,"acronym":4,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":112,"enrollmentInfo":113,"targetDuration":4,"studyType":22,"phases":115,"briefSummary":116,"conditions":117,"keywords":121,"overallStatus":47,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":59},"100516483","a-randomized-clinical-trial-comparing-active-versus-sham-t-pemf-headband-treatment-for-depression-100516483","NCT06005103","A Randomized Clinical Trial Comparing Active Versus Sham T-PEMF Headband Treatment for Depression","Active Versus Sham Transcranial Pulsed Electromagnetic Field Headband Treatment for Major Depression: a Study Protocol for a Double-blinded Randomized Trial","Inclusion Criteria:\n\n* Meeting the diagnostic criteria for moderate to severe depressive episode without psychotic symptoms according to the International Classification of Diseases and Related Health Problems 10th Revision (ICD-10)(The ICD-10 Classification of Mental and Behavioural Disorders: Diagnostic Criteria for Research 1993).\n* Female participants: Females in the fertile age must deliver a negative pregnancy test, or previously have been sterilized.\n* Female fertile participants: They must use safe contraceptive methods to be included in the study, and during the whole study.\n* Has given written, informed consent to the trial.\n\nExclusion Criteria:\n\n* Inability to speak or understand the Danish language.\n* A current high risk of suicide (a score of 2 or more on the HAM-D-17 item 3).\n* A co-morbid substance dependence.\n* Bipolar affective disorder.\n* Psychotic illness.\n* Dementia.\n* Other diagnoses of organic brain disease.\n* The participant has any kind of implant, e.g. pacemakers or cochlear implants.\n* Female participants: Pregnancy","65 Years",{"count":114,"type":21},117,[24],"An 8-week, two-armed, randomized-controlled trial that examines the antidepressant effect of treatment with transcranial pulsed electromagnetic fields (T-PEMF) in patients diagnosed with moderate to severe depression using using a new device, the MoodHeadBand (MHB).\n\nThe participants will use an active or placebo MHB for 30 minutes daily for 8 weeks.\n\nAdditionally, the following research questions will be answered:\n\n1\\. If there is a positive effect on the patients' emotional and non-emotional cognition after 8 weeks of active treatment compared to the sham group and if possible early changes in the emotional cognition can predict the treatment response after 8 weeks of treatment.\n\n1\\. If the T-PEMF treatment provides improvement in restorative sleep after 8 weeks of treatment",[34,118,119,120],"Severe Depressive Episode Without Psychotic Symptoms","Recurrent Depressive Disorder, Current Episode Moderate","Recurrent Depressive Disorder, Current Episode Severe Without Psychotic Symptoms",[122,123,124,92,125,126],"Randomized Controlled Trial","Depression","Transcranial Pulsed Electro-Magnetic Fields (T-PEMF)","Cognition","Sleep","2025-08-19",{"date":129,"type":51},"2025-08-26",{"date":131,"type":51},"2024-06-17",{"date":133,"type":21},"2026-08-30",{"name":135,"class":58},"Mental Health Centre Copenhagen, Bispebjerg and Frederiksberg Hospital"]